Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash & Equivalents (2020 - 2025)

Foghorn Therapeutics has reported Cash & Equivalents over the past 6 years, most recently at $80.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $80.9 million for Q4 2025, up 45.84% from a year ago — trailing twelve months through Dec 2025 was $80.9 million (up 45.84% YoY), and the annual figure for FY2025 was $80.9 million, up 45.84%.
  • Cash & Equivalents for Q4 2025 was $80.9 million at Foghorn Therapeutics, down from $89.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for FHTX hit a ceiling of $213.6 million in Q1 2022 and a floor of $50.6 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $71.4 million (2023), compared with a mean of $83.0 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 1829.97% in 2021 and later plummeted 76.3% in 2023.
  • Foghorn Therapeutics' Cash & Equivalents stood at $101.1 million in 2021, then tumbled by 48.37% to $52.2 million in 2022, then soared by 53.86% to $80.3 million in 2023, then tumbled by 30.97% to $55.5 million in 2024, then soared by 45.84% to $80.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $80.9 million (Q4 2025), $89.3 million (Q3 2025), and $72.6 million (Q2 2025) per Business Quant data.